Terapi Human Growth Hormone (HGH) untuk Anak dengan Non-Growth Hormone Deficiency (Non-GHD)
DOI:
https://doi.org/10.55175/cdk.v48i7.102Kata Kunci:
recombinant human growth hormone, non-growth hormone deficiency, Growth hormoneAbstrak
Growth hormone (GH) yang disekresikan oleh hipofisis anterior merupakan hormon yang berperan penting dalam pertumbuhan. Terapi GH mulai dikembangkan untuk anak non-GHD dan disetujui penggunaannya oleh FDA, EMA, dan FMDA. Tujuan terapi GH adalah agar dapat mencapai potensi tinggi dewasa dalam batas normal. Respons terhadap rhGH tergantung usia saat dimulainya terapi, onset pubertas, tinggi badan orang tua, usia tulang, dan nilai biokimia saat pemberian rhGH. Tantangan dalam pemberian rhGH adalah dosis, kepatuhan terhadap terapi, dan usia saat pemberian.
Growth hormone secreted by anterior pituitary is an essential hormone for growth. GH therapy is now widely used for non-GHD children and approved by FDA, EMA, and FMDA. The aim of GH therapy is to achieve potential normal body height in adulthood. Response to rhGH depends on age of therapy initiation, puberty, paternal height, bone age, and biochemical level. The current challenges of GH therapy are dosage, adherence, and age at initiation.
Unduhan
Referensi
Encyclopaedia Britannica. Growth hormone. Encyclopaedia Britannica, Inc. Cited 2019 Sept 17. Available from: URL: https://www.britannica.com/science/growthhormone.
Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescent: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr.DOI:10.1159/000452150.
Kumar PK, Menon RK. New insight into growth hormone’s actions on the macrophage: implications for non-growth-related actions of growth hormone. OA Biochemistry 2013;1(2):15.
Batubara JR. Controversy in Growth Hormone Treatment. In Proc 6th Pediatric Endocrinology Update; 2018 Apr 13-14; Bandung, Indonesia
Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-Term Safety of Recombinant Human Growth Hormone in Children. JCEM 2010;95:167-177. https://doi.org/10.1210/jc.2009-0178.
Aydin BK, Aycan Z, Siklar Z, Berberoglu M, Ocal G, Cetinkaya S, et al. Adherence to growth hormone therapy: results of a multicenter study. J Endocr Pract. 2014;20(1):46-51. doi: 10.4158/EP13194.OR
Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016. doi: 10.1530/EJE-16-0111
Pfaffle R. Hormone replacement therapy in children: The use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab 2015:1-14. http://dx.doi.org/10.1016/j.beem.2015.04.009
Richmond E, Rogol AD. Treatment of Growth Hormone Deficiency in Children, Adolescent, and at the Transitional Age. Best Prac Rese Clin Endocrinol Metab. 2016. Doi: 10.1016/j.beem.2016.11.005
Pozzobon G, Partenope C, Mora S, Garbetta G, Weber G, Barera G. Growth hormone therapy in children: predictive factors and short-term and long term response criteria. Springer Nature. https://doi.org/10.1007/s12020-019-02057-x.
Yang A, Choi JH, Sohn YB, Eom Y, Lee J, Yoo HW, et al. Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial. Orphanet J Rare Dis. 2019;14:216. https://doi.org/10.1186/s13023-019-1195-1.
Jensen RB, O’Connell SM, Kirk J, Donaldson M, Ivarsson SA, et al. A randomies controlled trial evaluating IGF-1 titration in contrast to current GH dosing strategies in children born small gestational age: the North European Small-for-Gestational-Age study. Eur J Endocrinol 2014;171:509-518. Doi: 10.1530/EJE-14-0419
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
